P. Tran

2.4k total citations · 1 hit paper
22 papers, 1.9k citations indexed

About

P. Tran is a scholar working on Psychiatry and Mental health, Pharmacology and Neurology. According to data from OpenAlex, P. Tran has authored 22 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Psychiatry and Mental health, 8 papers in Pharmacology and 2 papers in Neurology. Recurrent topics in P. Tran's work include Schizophrenia research and treatment (9 papers), Treatment of Major Depression (7 papers) and Electroconvulsive Therapy Studies (5 papers). P. Tran is often cited by papers focused on Schizophrenia research and treatment (9 papers), Treatment of Major Depression (7 papers) and Electroconvulsive Therapy Studies (5 papers). P. Tran collaborates with scholars based in United States, Australia and Canada. P. Tran's co-authors include Charles M. Beasley, Gary D. Tollefson, W. Satterlee, S.H. Hamilton, T.M. Sanger, Deborah N. D’Souza, J. F. Wernicke, Yili Pritchett, Satish Iyengar and Joel Raskin and has published in prestigious journals such as Neurology, Neuropsychopharmacology and Psychopharmacology.

In The Last Decade

P. Tran

19 papers receiving 1.7k citations

Hit Papers

Olanzapine versus Placebo and Haloperidol 1996 2026 2006 2016 1996 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Olanzapine versus Placebo and Haloperidol
    1996 643 citations Charles M. Beasley, Gary D. Tollefson et al. Neuropsychopharmacology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Tran United States 10 1.2k 453 323 292 266 22 1.9k
Heike Hunger Germany 13 1.5k 1.2× 273 0.6× 248 0.8× 282 1.0× 245 0.9× 14 1.9k
Г. Ингенито United States 14 1.9k 1.5× 347 0.8× 192 0.6× 268 0.9× 300 1.1× 33 2.3k
Mirza W. Ali United States 16 2.0k 1.6× 396 0.9× 209 0.6× 283 1.0× 292 1.1× 30 2.6k
Virginia L. Stauffer United States 30 2.3k 1.9× 296 0.7× 427 1.3× 400 1.4× 287 1.1× 85 2.7k
Franziska Schmid Germany 11 1.4k 1.1× 255 0.6× 232 0.7× 271 0.9× 234 0.9× 23 1.8k
Anutosh Ranjan Saha United States 9 2.0k 1.6× 375 0.8× 214 0.7× 288 1.0× 256 1.0× 13 2.6k
Pierre V. Trân United States 17 1.5k 1.2× 616 1.4× 113 0.3× 297 1.0× 304 1.1× 28 1.9k
Elyse Stock United States 15 2.5k 2.0× 334 0.7× 467 1.4× 387 1.3× 228 0.9× 44 3.0k
W.W. Fleischhacker Austria 27 1.5k 1.2× 409 0.9× 217 0.7× 387 1.3× 290 1.1× 58 2.5k
Caroline Corves Germany 6 1.7k 1.3× 311 0.7× 141 0.4× 360 1.2× 369 1.4× 11 2.2k

Countries citing papers authored by P. Tran

Since Specialization
Citations

This map shows the geographic impact of P. Tran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Tran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Tran more than expected).

Fields of papers citing papers by P. Tran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Tran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Tran. The network helps show where P. Tran may publish in the future.

Co-authorship network of co-authors of P. Tran

This figure shows the co-authorship network connecting the top 25 collaborators of P. Tran. A scholar is included among the top collaborators of P. Tran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Tran. P. Tran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Tran, P., et al.. (2024). Mixed neuroendocrine–nonneuroendocrine epithelial neoplasm of muscle invasive bladder cancer: a clinicopathologic case study. Journal of Surgical Case Reports. 2024(10). rjae612–rjae612.
2.
Tran, P., et al.. (2024). Rare melanosis in the urinary bladder and prostate: a case report. Journal of Surgical Case Reports. 2024(5).
3.
Bymaster, Frank P., et al.. (2013). Biopharmaceutical Characterization, Metabolism, and Brain Penetration of the Triple Reuptake Inhibitor Amitifadine. Drug Metabolism Letters. 7(1). 23–33. 2 indexed citations
4.
5.
Wernicke, J. F., Yili Pritchett, Deborah N. D’Souza, et al.. (2006). A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain. Neurology. 67(8). 1411–1420. 370 indexed citations
6.
Henry, Michael, Mark E. Schmidt, John Hennen, et al.. (2005). A Comparison of Brain and Serum Pharmacokinetics of R-Fluoxetine and Racemic Fluoxetine: A 19-F MRS Study. Neuropsychopharmacology. 30(8). 1576–1583. 64 indexed citations
7.
Wernicke, J. F., et al.. (2004). Antidepressants. Journal of Pain. 5(3). S48–S48. 8 indexed citations
8.
Gureje, Oye, Nicholas A Keks, David Grainger, et al.. (2003). Olanzapine vs risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Schizophrenia Research. 61(2-3). 303–314. 70 indexed citations
9.
Tran, P., et al.. (2002). Safety and tolerability of the antidepressant duloxetine. European Neuropsychopharmacology. 12. 215–216.
10.
Breier, Alan, P. Tran, John M. Herrera, Gary D. Tollefson, & Frank P. Bymaster. (2001). Current issues in the psychopharmacology of schizophrenia. Lippincott Williams & Wilkins eBooks. 31 indexed citations
11.
Meehan, Karena, Fan Zhang, S.R. David, et al.. (2001). A Double-Blind, Randomized Comparison of the Efficacy and Safety of Intramuscular Injections of Olanzapine, Lorazepam, or Placebo in Treating Acutely Agitated Patients Diagnosed With Bipolar Mania. Journal of Clinical Psychopharmacology. 21(4). 389–397. 171 indexed citations
12.
Bymaster, Frank P., P. Tran, Alan Breier, Nicholas Moore, & Gary D. Tollefson. (2000). The multi-acting-receptor-targeted-antipsychotic (MARTA) concept of the therapeutic action of olanzapine. Schizophrenia Research. 41(1). 235–235. 1 indexed citations
13.
Tran, P., et al.. (1998). Olanzapine in the treatment of schizoaffective disorder. Schizophrenia Research. 29(1-2). 151–151. 6 indexed citations
14.
Tran, P., et al.. (1997). Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatric Services. 48(12). 1571–1577. 59 indexed citations
15.
Shoshani, David, et al.. (1997). P.2.092 Clozapine-induced agranulocytosis: Can olanzapine be a safer alternative?. European Neuropsychopharmacology. 7. S221–S221. 1 indexed citations
16.
Beasley, Charles M., T.M. Sanger, W. Satterlee, et al.. (1996). Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology. 124(1-2). 159–167. 320 indexed citations
17.
Beasley, Charles M., Gary D. Tollefson, P. Tran, et al.. (1996). Olanzapine versus Placebo and Haloperidol. Neuropsychopharmacology. 14(2). 111–123. 643 indexed citations breakdown →
18.
Lü, Yifei, et al.. (1996). Olanzapine in the treatment of schizoaffective disorder. European Neuropsychopharmacology. 6. S4–106. 8 indexed citations
19.
Martín, Carmen, Laura A. Genduso, Dennis A. Revicki, et al.. (1996). Quality of life outcomes of olanzapine, a new atypical antipsychotic agent. Schizophrenia Research. 18(2-3). 130–131. 3 indexed citations
20.
Tran, P., Charles M. Beasley, G.D. Tollefson, et al.. (1996). Acute and long-term results of the dose ranging double-blind olanzapine trial. European Neuropsychopharmacology. 6. 58–59. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Heike Hunger Breakdown of academic impact, for papers by Г. Ингенито Breakdown of academic impact, for papers by Mirza W. Ali Breakdown of academic impact, for papers by Virginia L. Stauffer Breakdown of academic impact, for papers by Franziska Schmid Breakdown of academic impact, for papers by Anutosh Ranjan Saha Breakdown of academic impact, for papers by Pierre V. Trân Breakdown of academic impact, for papers by Elyse Stock Breakdown of academic impact, for papers by W.W. Fleischhacker Breakdown of academic impact, for papers by Caroline Corves
Rankless by CCL
2026